NYSE:RDY Dr. Reddy's Laboratories (RDY) Stock Price, News & Analysis $78.35 -0.44 (-0.56%) (As of 09/19/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About Dr. Reddy's Laboratories Stock (NYSE:RDY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$78.10▼$78.9350-Day Range$78.12▼$84.2152-Week Range$63.72▼$84.46Volume118,505 shsAverage Volume218,902 shsMarket Capitalization$13.08 billionP/E Ratio19.44Dividend Yield0.51%Price Target$87.00Consensus RatingHold Company OverviewDr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.Read More… Our #1 Ticker for the Rare "Retirement Window" (Ad)We've only seen this happen three times in the past 20 years... And every time - like clockwork - it's minted an entire new class of millionaires.Click here for our #1 "Retirement Window" Stock >>> Dr. Reddy's Laboratories Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 49th PercentileDr. Reddy's Laboratories scored higher than 49% of companies evaluated by MarketBeat, and ranked 651st out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingDr. Reddy's Laboratories has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.Amount of Analyst CoverageDr. Reddy's Laboratories has only been the subject of 1 research reports in the past 90 days.Read more about Dr. Reddy's Laboratories' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth0.49% Earnings GrowthEarnings for Dr. Reddy's Laboratories are expected to grow by 0.49% in the coming year, from $4.11 to $4.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dr. Reddy's Laboratories is 19.44, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 131.01.Price to Earnings Ratio vs. SectorThe P/E ratio of Dr. Reddy's Laboratories is 19.44, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 118.08.Price to Earnings Growth RatioDr. Reddy's Laboratories has a PEG Ratio of 1.74. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDr. Reddy's Laboratories has a P/B Ratio of 3.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Dr. Reddy's Laboratories' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.23% of the outstanding shares of Dr. Reddy's Laboratories have been sold short.Short Interest Ratio / Days to CoverDr. Reddy's Laboratories has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Dr. Reddy's Laboratories has recently decreased by 9.25%, indicating that investor sentiment is improving significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldDr. Reddy's Laboratories has a dividend yield of 0.50%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthDr. Reddy's Laboratories does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Dr. Reddy's Laboratories is 9.93%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Dr. Reddy's Laboratories will have a dividend payout ratio of 9.69% next year. This indicates that Dr. Reddy's Laboratories will be able to sustain or increase its dividend.Read more about Dr. Reddy's Laboratories' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.23% of the outstanding shares of Dr. Reddy's Laboratories have been sold short.Short Interest Ratio / Days to CoverDr. Reddy's Laboratories has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Dr. Reddy's Laboratories has recently decreased by 9.25%, indicating that investor sentiment is improving significantly. News and Social Media1.8 / 5News Sentiment0.24 News SentimentDr. Reddy's Laboratories has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Dr. Reddy's Laboratories this week, compared to 3 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dr. Reddy's Laboratories insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.00% of the stock of Dr. Reddy's Laboratories is held by insiders.Percentage Held by InstitutionsOnly 14.02% of the stock of Dr. Reddy's Laboratories is held by institutions.Read more about Dr. Reddy's Laboratories' insider trading history. RDY Stock News HeadlinesDr. Reddy's Laboratories Limited (NYSE:RDY) Forecasted to Earn FY2027 Earnings of $3.12 Per ShareSeptember 14, 2024 | americanbankingnews.comDr. Reddy's Laboratories Limited (RDY)September 11, 2024 | finance.yahoo.com“I’ll Give You the Knowledge and Confidence You Need to Make Your First Options Trade in Five Days or Less… Guaranteed!”Starting Monday, September 23 — a veteran 25-year Chicago Options Exchange market-maker will show you his UOA options secret that could help you consistently target gains of 126%… 245%… even 463% or more… Often in 30 days or less… No matter what the market is doing right now.September 19, 2024 | InvestorPlace (Ad)Dr. Reddy's Laboratories underperforms Tuesday when compared to competitorsSeptember 3, 2024 | marketwatch.comDr. Reddy's Laboratories underperforms Thursday when compared to competitorsAugust 29, 2024 | marketwatch.comDr. Reddy's Q1FY25 Financial ResultsJuly 27, 2024 | businesswire.comDr Reddys Laboratories earnings: here's what Wall Street expectsJuly 26, 2024 | markets.businessinsider.comDr. Reddy's Laboratories rises Tuesday, outperforms marketJuly 23, 2024 | marketwatch.comSee More Headlines RDY Stock Analysis - Frequently Asked Questions How have RDY shares performed this year? Dr. Reddy's Laboratories' stock was trading at $69.58 at the beginning of 2024. Since then, RDY stock has increased by 12.6% and is now trading at $78.35. View the best growth stocks for 2024 here. How were Dr. Reddy's Laboratories' earnings last quarter? Dr. Reddy's Laboratories Limited (NYSE:RDY) released its earnings results on Saturday, July, 27th. The company reported $1.00 earnings per share for the quarter, missing analysts' consensus estimates of $1.10 by $0.10. The company earned $919.80 million during the quarter, compared to analysts' expectations of $861.68 million. Dr. Reddy's Laboratories had a trailing twelve-month return on equity of 20.32% and a net margin of 19.28%. Who are Dr. Reddy's Laboratories' major shareholders? Top institutional shareholders of Dr. Reddy's Laboratories include Renaissance Technologies LLC (1.20%), Dimensional Fund Advisors LP (0.60%), Millennium Management LLC (0.20%) and Acadian Asset Management LLC (0.16%). How do I buy shares of Dr. Reddy's Laboratories? Shares of RDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Dr. Reddy's Laboratories own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dr. Reddy's Laboratories investors own include Siemens Aktiengesellschaft (SIEGY), Tata Motors (TTM), Infosys (INFY), HDFC Bank (HDB), Alibaba Group (BABA) and GSK (GSK). Company Calendar Last Earnings7/27/2024Ex-Dividend for 7/30 Dividend7/30/2024Dividend Payable7/30/2024Today9/19/2024Next Earnings (Estimated)10/25/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryPharmaceutical Products Current SymbolNYSE:RDY CUSIPN/A CIK1135951 Webwww.drreddys.com Phone914049002900Fax91-40-4900-2999Employees27,048Year Founded1984Price Target and Rating Average Stock Price Target$87.00 High Stock Price Target$87.00 Low Stock Price Target$87.00 Potential Upside/Downside+11.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$4.03 Trailing P/E Ratio19.44 Forward P/E Ratio19.06 P/E Growth1.74Net Income$668 million Net Margins19.28% Pretax Margin24.88% Return on Equity20.32% Return on Assets14.62% Debt Debt-to-Equity Ratio0.02 Current Ratio2.55 Quick Ratio1.90 Sales & Book Value Annual Sales$288.51 billion Price / Sales0.05 Cash Flow$5.01 per share Price / Cash Flow15.63 Book Value$20.17 per share Price / Book3.88Miscellaneous Outstanding Shares166,893,000Free Float163,555,000Market Cap$13.08 billion OptionableOptionable Beta0.55 Social Links This page (NYSE:RDY) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredForget ChatGPT: Follow the AI Retirement PlaybookEveryone’s talking about AI right now, but I’ve been talking about it for years. Follow this two-part playb...Brownstone Research | SponsoredDump Nvidia, Apple, and Tesla Before It’s Too LateThe financial world is on high alert. Billionaires like Warren Buffett, Jeff Bezos, and Elon Musk are dumpi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Dr. Reddy's Laboratories Limited You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Dr. Reddy's Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.